XML 81 R10.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Acquisitions | 12 Months Ended
--- | ---
Oct. 31, 2019
Business Combination And Asset Acquisition [Abstract] |
Acquisitions | Acquisitions The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2019, 2018 and 2017:
(In millions) | 2019 |  | 2018 |  | 2017
Technology | $ | 12.3 |  |  | $ | — |  |  | $ | 71.7 |
Customer relationships | 7.5 |  |  | 23.5 |  |  | 43.1 |
Trademarks | 10.2 |  |  | 100.0 |  |  | 7.1 |
Composite intangible asset | — |  |  | 1,061.9 |  |  | — |
Other | 0.1 |  |  | 4.2 |  |  | — |
Total identifiable intangible assets | $ | 30.1 |  |  | $ | 1,189.6 |  |  | $ | 121.9 |
Goodwill | 29.8 |  |  | 70.6 |  |  | 123.1 |
Net tangible assets (liabilities) | 7.3 |  |  | 59.6 |  |  | (4.8 | )
Total purchase price | $ | 67.2 |  |  | $ | 1,319.8 |  |  | $ | 240.2 |
All the acquisitions were funded by cash generated from operations or facility borrowings. For business acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For asset acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition. We believe these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new or complementary products and services. Fiscal Year 2019 Purchase price allocation for the acquisitions in fiscal year 2019 are completed. On December 31, 2018, CooperSurgical completed the acquisition of Incisive Surgical Inc., a privately-held U.S. medical device company that develops mechanical surgical solutions for skin closure. On December 28, 2018, CooperVision completed the acquisition of Blanchard Contact Lenses. Blanchard is a privately-held scleral lens company, which expands CooperVision's specialty and scleral lens portfolio. The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our reported consolidated financial results. Fiscal Year 2018 PARAGARD On November 1, 2017, CooperSurgical acquired the assets of the PARAGARD Intrauterine System (IUS) business (PARAGARD) from Teva Pharmaceuticals Industries Limited for $1.1 billion. This asset acquisition broadened and strengthened CooperSurgical's product portfolio. PARAGARD® is the only hormone-free, long lasting, reversible contraceptive approved by the United States Food and Drug Administration (FDA) available in the United States. The Company has accounted for the acquisition of PARAGARD as a purchase of assets in accordance with ASC Topic 805, Business Combinations, and ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, whereby the Company recognized assets acquired based on their estimated relative fair values on the acquisition date. Due to the required screening test, the acquisition does not meet the definition of a business as substantially all the fair value of the gross assets acquired is concentrated in a single identifiable asset. The Company retained independent appraisers to advise management in the determination of the relative fair value of the various assets acquired and liabilities assumed. The values assigned in these financial statements represent management’s best estimate of relative fair values as of the acquisition date. The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model:
(In millions) | Relative Fair Value
Composite intangible asset (1) | $ | 1,061.9 |
Assembled workforce intangible asset (2) | 1.2 |
Property, plant and equipment | 2.0 |
Inventory (3) | 47.3 |
Other assets | 9.4 |
Total assets acquired | $ | 1,121.8 |
Less: liabilities assumed | 16.4 |
Total Purchase Price | $ | 1,105.4 |
The Company proportionally allocated the acquisition costs to the net assets acquired. The acquisition-related costs included advisory, legal, valuation and other professional fees. (1) Composite Intangible asset consists of technology, trade name, New Drug Application (NDA) approval and physician relationships, which have been valued as a single composite intangible asset as they are inextricably linked. The composite asset was identified as the primary asset acquired, was valued using the Multi-Period Excess Earnings Method and will be amortized over 15 years. (2) An assembled workforce was recognized as a separate acquired intangible asset, given the purchase of assets and will be amortized over 5 years. (3) Inventory relative fair value includes step up of $45.4 million. As PARAGARD was considered an asset purchase as opposed to a business acquisition in accordance with the guidance under ASC 805, Business Combinations, and ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, the Company has not included proforma financial information which is applicable for a business acquisition. Other Acquisitions On April 3, 2018, CooperSurgical completed the acquisition of The LifeGlobal Group (LifeGlobal). LifeGlobal was a privately held company that specializes primarily in in-vitro fertilization (IVF) media. LifeGlobal’s product categories include media products as well as IVF laboratory air filtration products and dishware. On January 4, 2018, CooperVision acquired Blueyes Ltd, a long-standing distribution partner, with a leading position in the distribution of contact lenses to the Optical and Pharmacy sector in Israel. On December 1, 2017, CooperVision acquired Paragon Vision Sciences, a leading provider of orthokeratology (ortho-k) specialty contact lenses and oxygen permeable rigid contact lens materials. Ortho-k contact lenses are overnight lenses which enable corneal topography correction for myopia (nearsightedness) patients. Fiscal Year 2017 On August 3, 2017, CooperVision completed the acquisition of Procornea Holding B.V. (Procornea). Procornea is a Netherlands based manufacturer and distributor of specialty contact lenses, mainly ortho-k which expands CooperVision's access to myopia (nearsightedness) management markets with new products. On June 30, 2017, CooperVision completed the acquisition of Grand Vista LLC, a long-standing distribution partner in Russia. Grand Vista LLC is engaged in contact lens and contact lens solutions and lens care product distribution business in Russia. On November 4, 2016, CooperSurgical completed the acquisition of Wallace, the IVF segment of Smiths Medical International, Ltd., a division of Smiths Group plc. Wallace manufactures a range of IVF and OB/GYN products.

X
- Definition Business Combination And Asset Acquisition [Abstract] + References No definition available. + Details
Name: | coo_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | coo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination And Asset Acquisition [Text Block] + References No definition available. + Details
Name: | coo_BusinessCombinationAndAssetAcquisitionTextBlock
Namespace Prefix: | coo_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration